These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 12386525)
1. [Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease]. Dartigues JF; Goulley F; Bourdeix I; Péré JJ; Barberger-Gateau P Rev Neurol (Paris); 2002 Sep; 158(8-9):807-12. PubMed ID: 12386525 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427 [TBL] [Abstract][Full Text] [Related]
3. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A; Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702 [TBL] [Abstract][Full Text] [Related]
4. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. Bilikiewicz A; Opala G; Podemski R; Puzyński S; Łapin J; Sołtys K; Ochudło S; Barcikowska M; Pfeffer A; Bilińska M; Paradowski B; Parnowski T; Gabryelewicz T Med Sci Monit; 2002 Feb; 8(2):PI9-15. PubMed ID: 11859291 [TBL] [Abstract][Full Text] [Related]
5. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693 [TBL] [Abstract][Full Text] [Related]
6. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553 [TBL] [Abstract][Full Text] [Related]
7. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273 [TBL] [Abstract][Full Text] [Related]
8. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542 [TBL] [Abstract][Full Text] [Related]
10. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032 [TBL] [Abstract][Full Text] [Related]
11. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Gauthier S; Juby A; Morelli L; Rehel B; Schecter R; Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Burns A; Spiegel R; Quarg P Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039 [TBL] [Abstract][Full Text] [Related]
13. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333 [TBL] [Abstract][Full Text] [Related]
15. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors. Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422 [TBL] [Abstract][Full Text] [Related]
16. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. Farlow MR; Lilly ML; BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242 [TBL] [Abstract][Full Text] [Related]
17. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Erkinjuntti T; Skoog I; Lane R; Andrews C Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954 [TBL] [Abstract][Full Text] [Related]
18. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746 [TBL] [Abstract][Full Text] [Related]
19. The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer's disease. Hatoum HT; Lin SJ; Arcona S; Thomas SK; Koumaras B; Mirski D J Am Med Dir Assoc; 2005; 6(4):238-45. PubMed ID: 16005409 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study. Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]